BYDUREON

Facts of Bydureon (exenatide)

Medicine Name: BYDUREON
Generic Name: exenatide
Approval Date: 02/28/2014
Company Name: Amylin Pharmaceuticals, Inc.
Available as (Form & Strength): 2 mg exenatide for extended-release injectable suspension

BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settingsBYDUREON is an extended-release fo rmulation of exenatide. Do not co-administer with BYETTA.

Limitation of Use

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise
Should not be used to treat type 1 diabetes or diabetic ketoacidosis
Use with insulin has not been studied and is not recommended
Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis

BYDUREON is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus, and should be used along with diet and exercise.
BYDUREON is a long – acting form of the medication contained in BYETTA. Do not use BYDUREON and BYETTA together.
BYDUREON is not recommended as the first choice of medication fo r treating diabetes.
BYDUREON is not insulin.
It is not known if BYDUREON is safe and effective when used with insulin.
BYDUREON is no t for use in people with type 1 diabetes or people with a condition caused by very high blood sugar (diabetic ketoacidosis ).
It is not known if BYDUREON is safe and effective in children. BYDUREON is not recommended for use in children.
It is not known if BYDUREON is safe and effective in people who have a history of pancreatitis.
BYDUREON has not been studied in people who have severe kidney problems.